Association of Treatment for Hyperlipidemia with Decreased Total Mortality in Japanese Individuals: the Yamagata (Takahata) Study

被引:15
作者
Daimon, Makoto [1 ]
Oizumi, Toshihide [2 ]
Kameda, Wataru [2 ]
Matsui, Jun [1 ]
Murakami, Hiroshi [1 ]
Ueno, Yoshiyuki [3 ]
Kubota, Isao [3 ]
Yamashita, Hidetoshi [3 ]
Kayama, Takamasa [3 ]
Kato, Takeo [2 ,3 ]
机构
[1] Hirosaki Univ, Grad Sch Med, Dept Endocrinol & Metab, Hirosaki, Aomori 0368562, Japan
[2] Yamagata Univ, Fac Med, DNHMED, Yamagata 990, Japan
[3] Yamagata Univ, Fac Med, Inst Promot Med Sci Res, Yamagata 990, Japan
关键词
Population-based; Hyperlipidemia; Cohort; Mortality; TYPE-2; DIABETES-MELLITUS; CORONARY-HEART-DISEASE; CARDIOVASCULAR-DISEASE; PRIMARY-PREVENTION; RISK-FACTORS; HYPERTENSIVE PATIENTS; EVENTS; ATORVASTATIN; CHOLESTEROL; PRAVASTATIN;
D O I
10.5551/jat.29181
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Aim: To evaluate the effects of treatment for hyperlipidemia on total mortality, we examined the association with adjustments for multiple factors, including those related to general health, such as blood hemoglobin and serum levels of albumin, adiponectin, brain natriuretic peptide, and lipids, using a prospective cohort study of a general Japanese population. Methods: The population-based, longitudinal Takahata study enrolled 3,291 Japanese individuals (1515 male, 1776 female; age: 62.5 +/- 10.3 years) between 2004 and 2006. The incidence and causes of death were annually monitored until January 10, 2012 (median follow-up period: 2,655 days). Results: During the follow-up period, there were 169 deaths. The Cox proportional hazard regression model analysis used to adjust for factors related to general health condition, cardiovascular disease risks, and serum lipid levels showed a significant association between treatment for hyperlipidemia and decreased total mortality compared with no treatment for hyperlipidemia [hazard ratio (HR): 0.24; 95% confidence interval (CI): 0.08-0.69) and subjects without hyperlipidemia (HR: 0.34; 95% CI: 0.12-0.96). The Cox proportional hazard regression model analysis with adjustments for factors related to general health conditions showed a significantly lower total mortality in subjects without hyperlipidemia than that in subjects with untreated hyperlipidemia (HR: 0.70; 95% CI: 0.50-0.99). Conclusions: Not only antihyperlipidemic drugs used but also selection bias and non-evaluated factors, such as socio-economic status, educational level, health literacy, and daily nutrition, affected the results. Subjects taking treatment for hyperlipidemia were found to have reduced total mortality, which was independent of serum lipid levels.
引用
收藏
页码:1030 / 1039
页数:10
相关论文
共 54 条
[1]  
Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
[2]  
2-S
[3]  
Amarenco P, 2006, NEW ENGL J MED, V355, P549
[4]  
[Anonymous], 2000, J Atheroscler Thromb, V7, P110
[5]  
[Anonymous], 1971, Br Med J, V4, P767
[6]  
[Anonymous], 2000, Ital Heart J, V1, P810
[7]   Serum lipid survey and its recent trend in the general Japanese population in 2000 [J].
Arai, H ;
Yamamoto, A ;
Matsuzawa, Y ;
Saito, Y ;
Yamada, N ;
Oikawa, S ;
Mabuchi, H ;
Teramoto, T ;
Sasaki, J ;
Nakaya, N ;
Itakura, H ;
Ishikawa, Y ;
Ouchi, Y ;
Horibe, H ;
Kita, T .
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2005, 12 (02) :98-106
[8]   Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[9]  
Bestehorn HP, 1997, EUR HEART J, V18, P226
[10]   Use of Fibrates and Cancer Risk: A Systematic Review and Meta-Analysis of 17 Long-Term Randomized Placebo-Controlled Trials [J].
Bonovas, Stefanos ;
Nikolopoulos, Georgios K. ;
Bagos, Pantelis G. .
PLOS ONE, 2012, 7 (09)